Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359073 | 0.91 | CTBP2 (0.54) | L3MBTL1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL165944 | 0.89 | CTBP2 (0.57) | L3MBTL1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL11382971 | 0.89 | RAB9A (0.57) | L3MBTL1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL16171153 | 0.88 | MEN1 (0.52) | L3MBTL1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL3073424 | 0.85 | NT5E (0.55) | RAB9ANPC1SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL3281032 | 0.85 | KDM4E (0.58) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25760942 | 0.84 | CTBP2 (0.49) | L3MBTL1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL3283011 | 0.83 | KCNK3 (0.51) | RAB9ANPC1SMN1; SMN2LMNAHTT | |
| SCHEMBL6525838 | 0.83 | L3MBTL1 (0.53) | L3MBTL1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL6525843 | 0.83 | L3MBTL1 (0.53) | L3MBTL1RAB9ANPC1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106547168-B | Black matrix material composition and application | 深圳市华星光电技术有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-2468708-B1 | Catalytic decarboxylative cross-ketonisation of aryl- and alkylcarboxylic acids using iron catalysts | COGNIS IP MAN GMBH (DE) | 2016-11-09 | — | — | EP | disclosed |
| EP-2468708-B1 | Catalytic decarboxylative cross-ketonisation of aryl- and alkylcarboxylic acids using iron catalysts | COGNIS IP MAN GMBH (DE) | 2016-11-09 | — | — | EP | disclosed |
| EP-2018364-B1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2468708-A1 | Catalytic decarboxylative cross-ketonisation of aryl- and alkylcarboxylic acids using iron catalysts | Cognis IP Management GmbH (DE) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468708-A1 | Catalytic decarboxylative cross-ketonisation of aryl- and alkylcarboxylic acids using iron catalysts | Cognis IP Management GmbH (DE) | 2012-06-27 | — | — | EP | disclosed |
| US-7709507-B2 | Therapeutic fluoroethyl ureas | ALLERGAN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-2018364-A1 | THERAPEUTIC FLUOROETHYL UREAS | Allergan, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | disclosed |
| US-4009022-A | Selective antagonists for triazine herbicides | ROHM AND HAAS COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | SLC14A1, MAPT, UTS2R | L3MBTL1 1009/4885RAB9A 684/4885NPC1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.